奥拉帕利和度伐利尤单抗用于DNA损伤修复改变和生化复发前列腺癌患者的研究 - Suppr

Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate Cancer.

作者信息

Autio Karen A, McHugh Deaglan J, Rathkopf Dana E, Xiao Han, Merugu Swathi, Wong Phillip, Jan Mehrin, Dorff Tanya B, Heath Elisabeth I, Scher Howard I

机构信息

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Weill Cornell Medical College, New York, NY, USA.

出版信息

J Immunother Precis Oncol. 2025 Apr 23;8(2):172-176. doi: 10.36401/JIPO-24-36. eCollection 2025 May.

DOI:10.36401/JIPO-24-36

PMID:40270785

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12010483/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/170b/12010483/20e1a52e4173/10.36401_JIPO-24-36-f01.jpg

相似文献

Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate Cancer.

J Immunother Precis Oncol. 2025 Apr 23;8(2):172-176. doi: 10.36401/JIPO-24-36. eCollection 2025 May.

Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trial.

J Gynecol Oncol. 2025 Jul;36(4):e118. doi: 10.3802/jgo.2025.36.e118.

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.

J Immunother Cancer. 2018 Dec 4;6(1):141. doi: 10.1186/s40425-018-0463-2.

Cost-effectiveness of enzalutamide with androgen-deprivation therapy (ADT) versus ADT alone for the treatment of high-risk biochemically recurrent non-metastatic castration-sensitive prostate cancer in Canada.

J Med Econ. 2025 Dec;28(1):766-777. doi: 10.1080/13696998.2025.2503660. Epub 2025 May 23.

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.

BMC Cancer. 2020 Aug 10;20(1):748. doi: 10.1186/s12885-020-07253-x.

Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation.

Target Oncol. 2025 May 21. doi: 10.1007/s11523-025-01146-4.

PARP inhibitor olaparib induces DNA damage and acts as a drug sensitizer in an in vitro model of canine hematopoietic cancer.

BMC Vet Res. 2025 Jul 5;21(1):439. doi: 10.1186/s12917-025-04880-z.

Olaparib for the treatment of metastatic prostate cancer.

Future Oncol. 2021 Jul;17(19):2413-2429. doi: 10.2217/fon-2020-1245. Epub 2021 Mar 26.

The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis.

BMC Cancer. 2024 Jun 8;24(1):706. doi: 10.1186/s12885-024-12388-2.

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.

J Immunother Cancer. 2019 Jul 25;7(1):197. doi: 10.1186/s40425-019-0680-3.

本文引用的文献

Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled Trial.

JAMA Oncol. 2024 Oct 1;10(10):1400-1408. doi: 10.1001/jamaoncol.2024.3074.

A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR).

Oncologist. 2024 May 3;29(5):450-e725. doi: 10.1093/oncolo/oyae030.

Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.

N Engl J Med. 2023 Oct 19;389(16):1453-1465. doi: 10.1056/NEJMoa2303974.

Rucaparib or Physician's Choice in Metastatic Prostate Cancer.

N Engl J Med. 2023 Feb 23;388(8):719-732. doi: 10.1056/NEJMoa2214676. Epub 2023 Feb 16.

Therapeutic targeting of tumour myeloid cells.

Nat Rev Cancer. 2023 Apr;23(4):216-237. doi: 10.1038/s41568-022-00546-2. Epub 2023 Feb 6.

Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.

Eur Urol. 2023 Mar;83(3):267-293. doi: 10.1016/j.eururo.2022.11.002. Epub 2022 Dec 6.

Circulating myeloid-derived suppressor cells and survival in prostate cancer patients: systematic review and meta-analysis.

Prostate Cancer Prostatic Dis. 2023 Mar;26(1):41-46. doi: 10.1038/s41391-022-00615-5. Epub 2022 Nov 21.

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.

Eur Urol Open Sci. 2021 Nov 17;34:70-78. doi: 10.1016/j.euros.2021.09.015. eCollection 2021 Dec.

The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer.

Urol Clin North Am. 2020 Nov;47(4):457-467. doi: 10.1016/j.ucl.2020.07.004.

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.

N Engl J Med. 2020 Dec 10;383(24):2345-2357. doi: 10.1056/NEJMoa2022485. Epub 2020 Sep 20.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate Cancer.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献